The PAF-acether receptor antagonist BN-52021 inhibits mediator release during guinea-PIG active lung anaphylaxis

Pharmacological research communications Pub Date : 1988-12-01 DOI:10.1016/S0031-6989(88)80726-4

Berti F. , Galli G. , Magni F. , Rossoni G. , Villa L. , Puglisi L. , Pasargiklian R. , P. Braquet

{"title":"The PAF-acether receptor antagonist BN-52021 inhibits mediator release during guinea-PIG active lung anaphylaxis","authors":"Berti F. , Galli G. , Magni F. , Rossoni G. , Villa L. , Puglisi L. , Pasargiklian R. , P. Braquet","doi":"10.1016/S0031-6989(88)80726-4","DOIUrl":null,"url":null,"abstract":"<div><p>An anaphylactic reaction was induced with the specific antigen (1 mg Ovalbumin) in perfused lungs from actively sensitized guinea-pigs in order to evaluate the ability of the ginkgolide BN-52021 (0.4, 4, 40 ug/ml) to modulate the mediator release. The ginkgolide reduces in a dose dependent manner the release of histamine (22%, 45% and 75% of inhibition), TXB<sub>2</sub> (77% of inhibition at the maximal dose used) and of SRS-A to a lower extent (only 33% at the higher dose). BN-52021 was still powerful in reducing histamine release induced by immunological reaction in indomethacin treated animals. In conclusion, the present “in-vitro” results confirm the beneficial activity of this ginkgolide, already demonstrated by the same Authors in “in-vivo” experiment, in anaphylactic reactions, and further substantiate the wider spectrum of action of the ginkgolide beside its specific PAF receptor antagonistic activity.</p></div>","PeriodicalId":19810,"journal":{"name":"Pharmacological research communications","volume":"20 12","pages":"Pages 1047-1059"},"PeriodicalIF":0.0000,"publicationDate":"1988-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0031-6989(88)80726-4","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0031698988807264","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 3

Abstract

An anaphylactic reaction was induced with the specific antigen (1 mg Ovalbumin) in perfused lungs from actively sensitized guinea-pigs in order to evaluate the ability of the ginkgolide BN-52021 (0.4, 4, 40 ug/ml) to modulate the mediator release. The ginkgolide reduces in a dose dependent manner the release of histamine (22%, 45% and 75% of inhibition), TXB₂ (77% of inhibition at the maximal dose used) and of SRS-A to a lower extent (only 33% at the higher dose). BN-52021 was still powerful in reducing histamine release induced by immunological reaction in indomethacin treated animals. In conclusion, the present “in-vitro” results confirm the beneficial activity of this ginkgolide, already demonstrated by the same Authors in “in-vivo” experiment, in anaphylactic reactions, and further substantiate the wider spectrum of action of the ginkgolide beside its specific PAF receptor antagonistic activity.

查看原文本刊更多论文

paf -乙醚受体拮抗剂BN-52021抑制豚鼠活动性肺过敏反应期间介质释放

用特异性抗原(1 mg卵白蛋白)诱导主动致敏豚鼠肺灌注产生过敏反应，以评价银杏内酯BN-52021(0.4、4、40 ug/ml)调节介质释放的能力。银杏内酯以剂量依赖的方式降低组胺(22%、45%和75%的抑制作用)、TXB2(最大剂量时77%的抑制作用)和SRS-A的释放，但降低程度较低(高剂量时仅33%)。BN-52021对吲哚美辛治疗动物免疫反应诱导的组胺释放仍有较强的抑制作用。总之，目前的“体外”实验结果证实了银杏内酯在过敏反应中的有益活性，并进一步证实了银杏内酯在其特异性PAF受体拮抗活性之外的更广泛的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacological research communications

自引率

0.00%

发文量